First National Bank of Omaha Sells 9,594 Shares of Boston Scientific Corporation (BSX)

First National Bank of Omaha lowered its position in Boston Scientific Corporation (NYSE:BSX) by 4.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 212,515 shares of the medical equipment provider’s stock after selling 9,594 shares during the period. First National Bank of Omaha’s holdings in Boston Scientific Corporation were worth $5,891,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of BSX. Guardian Life Insurance Co. of America increased its position in shares of Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 49 shares during the last quarter. First Personal Financial Services increased its position in Boston Scientific Corporation by 0.9% in the first quarter. First Personal Financial Services now owns 9,107 shares of the medical equipment provider’s stock valued at $226,000 after buying an additional 80 shares during the last quarter. Cleararc Capital Inc. increased its position in Boston Scientific Corporation by 0.8% in the first quarter. Cleararc Capital Inc. now owns 33,322 shares of the medical equipment provider’s stock valued at $829,000 after buying an additional 251 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its position in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 338 shares during the last quarter. Finally, Checchi Capital Advisers LLC increased its position in Boston Scientific Corporation by 2.6% in the first quarter. Checchi Capital Advisers LLC now owns 13,553 shares of the medical equipment provider’s stock valued at $337,000 after buying an additional 349 shares during the last quarter. 91.96% of the stock is currently owned by institutional investors and hedge funds.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 26.83 on Friday. Boston Scientific Corporation has a 1-year low of $19.67 and a 1-year high of $28.51. The stock has a market capitalization of $36.77 billion, a price-to-earnings ratio of 48.00 and a beta of 1.09. The stock’s 50 day moving average is $27.64 and its 200 day moving average is $25.93.

Boston Scientific Corporation (NYSE:BSX) last issued its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period in the previous year, the business posted $0.27 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. On average, equities analysts forecast that Boston Scientific Corporation will post $1.26 EPS for the current year.

Several equities analysts recently issued reports on BSX shares. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. Oppenheimer Holdings, Inc. set a $27.00 target price on Boston Scientific Corporation and gave the company a “hold” rating in a research report on Friday, April 28th. Goldman Sachs Group, Inc. (The) started coverage on Boston Scientific Corporation in a research report on Tuesday, May 16th. They issued a “neutral” rating and a $28.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price (up from $29.00) on shares of Boston Scientific Corporation in a research report on Thursday, April 27th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $31.00 target price (up from $27.00) on shares of Boston Scientific Corporation in a research report on Wednesday, June 28th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation has an average rating of “Buy” and an average target price of $30.06.

In other Boston Scientific Corporation news, SVP Wendy Carruthers sold 12,433 shares of the company’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $26.75, for a total transaction of $332,582.75. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Kevin J. Ballinger sold 28,864 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $26.14, for a total transaction of $754,504.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 236,489 shares of company stock worth $6,440,888. Company insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.